4D Molecular Therapeutics (FDMT) Equity Average (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Equity Average data on file, last reported at $478.8 million in Q1 2026.

• Equity Average for Q1 2026 came in at $478.8 million, down 2.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $478.8 million (down 2.33% YoY), and the FY2025 annual result was $508.1 million, up 24.17% from the prior year.
• Equity Average advanced to $478.8 million in Q1 2026 per FDMT's latest filing, from $437.3 million in the prior quarter.
• Over five years, Equity Average peaked at $594.5 million in Q2 2024 and troughed at $225.0 million in Q1 2023.
• A 5-year average of $390.4 million and a median of $394.9 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average soared 118.65% in 2024, then tumbled 30.79% in 2025.
• A 5-year view of Equity Average shows it stood at $241.4 million in 2022, then jumped by 32.1% to $318.9 million in 2023, then soared by 66.76% to $531.8 million in 2024, then slipped by 17.76% to $437.3 million in 2025, then advanced by 9.47% to $478.8 million in 2026.
• Business Quant data shows FDMT's Equity Average at $478.8 million in Q1 2026, $437.3 million in Q4 2025, and $394.9 million in Q3 2025.